Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Harrow Inc Com

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Harrow Health (HROW – Research Report) and Butterfly...

Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and Butterfly Network (BFLY)

Harrow Health (HROW) Receives a Buy from Lake Street

Lake Street Sticks to Their Buy Rating for Harrow Health (HROW)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Harrow Health (HROW – Research Report), Ardelyx (ARD...

Current Quarter	$0.45	Next Quarter	$-0.12
Current Year	$0.69	Next Year	$1.54
QoQ Growth	-126.7%	YoY Growth	+123.2%
3Y EPS CAGR	+10.8%	Target Price	$71.43
Consensus	Buy	Upside	+83.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HROW	$38.91	+3.32%	565.53K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HROW	$38.91	+3.3%	565.53K
3
4
5
6

HROW

HROW

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Harrow Inc Com Data in Excel

Get Harrow Inc Com Data in Excel